Anti-Human VEGFR2/KDR/Flk-1 Reference Antibody (MSB-0254, RUO) (HW338086)

Name: Anti-Human VEGFR2/KDR/Flk-1 Reference Antibody (MSB-0254, RUO)
Brand: abinScience
SKU: HW338086
Price: 220 USD
Availability: InStock

Datasheet Share product Copy info

Price(USD):

Spec:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Number:

Get quote

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.	HW338086
Species reactivity	Human
Applications	ELISA, Bioactivity: FCM, Functional assay, Research in vivo
Host species	Human
Clonality	Monoclonal
Isotype	IgG
Clone ID	MSB-0254
Target	CD309, EC:2.7.10.1, FLK-1, FLK1, Fetal liver kinase 1, KDR, Kinase insert domain receptor, Protein-tyrosine kinase receptor flk-1, VEGFR-2, VEGFR2, Vascular endothelial growth factor receptor 2
Endotoxin level	< 10 EU/mg
Purity	>95% as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	P35968
Form	Liquid
Storage buffer	0.01M PBS pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternate Names	MSB-0254, MSB0254, MSB0254
Background	Vascular endothelial growth factor receptor 2 (CD309/VEGFR-2) is a ~151 kDa protein. Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. CD309 is the therapeutic target of ramucirumab (Cyramza).
References	1. Chen S, et al. Anti-VEGFR2 monoclonal antibody(MSB0254) inhibits angiogenesis and tumor growth by blocking the signaling pathway mediated by VEGFR2 in glioblastoma. Biochem Biophys Res Commun. 2022 May 14;604:158-164. [HW338086]
Note	For research use only. Not suitable for clinical or therapeutic use.